Pro Medicus Ltd

PME: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
fwLOCK|cmjn?LOCK|v^@zB!

Pro Medicus Earnings: Small Margin Expansion and Key Academic Hospital Market Is Limited

Pro Medicus’ revenue growth barely outstripped costs. Interim 2026 EBIT grew 30% with revenue up 28% on contract wins. However, EBIT margin expanded just 70 basis points to 73%, with employee expense growing 44%. Shares fell 24%.

Sponsor Center